VST LLC — Department of Health and Human Services SBIR Phase I: This project aims to evaluate and compare a new soluble inulin microparticle adjuvant alon
VST LLC — SBIR Phase I award from Department of Health and Human Services.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Health and Human Services in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $225,000. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Amount
- $225,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- NAICS
- —
- Place of performance
- SD
- Period
- —
Description
This project aims to evaluate and compare a new soluble inulin microparticle adjuvant along with approved human adjuvants alum and ISA-51VG (Seppic) in a vaccine study utilizing the company?s Rift Valley Fever virus (RVFV) recombinant protein subunit vaccine. The new adjuvant may have potential commercial applications for both human and veterinary vaccines for Rift Valley Fever. PUBLIC HEALTH RELEVANCE